Founded in New York City, SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company dedicated to developing novel therapies for various cancer indications. The company's core mission is to advance innovative oncology treatments to improve patient outcomes globally. SELLAS' product pipeline includes galinpepimut-S (GPS), an immunotherapeutic agent targeting the Wilms tumor protein (WT1), and SLS009, a highly selective therapeutic candidate.
SELLAS Life Sciences has garnered attention from notable investors and industry experts, contributing to its reputation in the biopharmaceutical sector. The company has achieved significant milestones, including successful clinical trials and regulatory advancements for its leading product candidates. SELLAS' impact is evident in its commitment to addressing unmet medical needs in oncology, positioning it as a key player in the fight against cancer.
